KC-3878

293T-CD38-Cell-Line

34952

Home » 293T-CD38-Cell-Line

Background of 293T-CD38-Cell-Line

The protein encoded by CD38 is a non lineage restricted type II transmembrane glycoprotein, expressed in B cells, T cells, NK cells, myeloid cells, etc., regulating cell activation, migration, and inflammatory response. It has dual activities of ADP ribosyl cyclase and cyclic ADP ribosyl hydrolase, catalyzing NAD+metabolism. Interacting with CD31, mediating leukocyte adhesion and migration, affecting the progression of inflammation or autoimmune diseases. The CD38 gene plays a central role in the immune, metabolic, and cellular signaling networks, and its multifunctionality makes it a therapeutic target for various diseases, particularly in the fields of tumor immunity and aging. Future research may further reveal its potential in metabolic and neurodegenerative diseases.

Specifications

Catalog Number	KC-3878
Cell Line Name	293T-CD38-Cell-Line
Host Cell Line	293T
Description	Stable 293T clone expressing exogenous CD38 gene
Quantity	One vial of frozen cells (≥2-10⁶/vial)
Stability	Stable in culture over a minimum of 10 passages
Application	Drug screening and biological assays
Freezing Medium	70% DMEM + 20% FBS + 10% DMSO
Propagation Medium	DMEM + 10% FBS + 1μg/mL Puromycin
Selection Marker	Puromycin
Morphology	Epithelial
Subculture	Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 10⁵ cells/mL
Incubation	37 °C with 5% CO₂
Storage	Liquid nitrogen immediately upon receiving
Doubling Time	Approximately 30 hours
Mycoplasma Status	Negative
In Vivo Validation	NA

Cell Line Generation

293T-CD38-cell-line was generated using a lentiviral vector expressing the CD38 sequence.

Characterization

Figure 1: Characterization of CD38 overexpression in the 293T-CD38 stable clone using FACS.

Figure 2: Characterization of CD38 overexpression in the 293T-CD38 stable clone using qPCR.

Cell Resuscitation

1. Prewarm culture medium (DMEM supplemented with 10% FBS and 1μg/mL puromycin)in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO₂ incubator.
8. Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 10⁵ cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% DMEM + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3×10⁶ cells/mL in chilled freezing medium.
6. Aliquot 1 mL of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage.

References

1.Wang X, Li L, Song X, Fang K, Chang X. A high proportion of CD38 (high) CD16 (low) NK cells in colorectal cancer can interrupt immune surveillance and favor tumor growth. Cancer Immunol Immunother. 2025 Jul 12;74(8):263. doi: 10.1007/s00262-025-04044-w. PMID: 40650701; PMCID: PMC12255634.
2.Dwyer LR, DeRogatis AM, Clancy S, Gouirand V, Chien C, Rogers EE, Oltman SP, Jelliffe-Pawlowski LL, Lynch SV, Rutishauser RL, Wagner A, Combes AJ, Scharschmidt TC. CD38 expression by neonatal human naïve CD4 + T cells shapes their distinct metabolic state and tolerogenic potential. bioRxiv [Preprint]. 2025 Jun 28:2025.01.02.631038. doi: 10.1101/2025.01.02.631038. PMID: 40667020; PMCID: PMC12262530.
3.Nabi-Afjadi M, Dabirmanesh B, Asghari SM, Ramezanpour S, Fathollahi Y, Khajeh K. Design, synthesis, and evaluation of the effect of potential peptides against CD38: An in silico and in vitro study. Biomed Pharmacother. 2025 Jul 12;189:118347. doi: 10.1016/j.biopha.2025.118347. Epub ahead of print. PMID: 40652724.

Use License Agreement

Research Use Only.

Not for use in diagnostic procedures or therapeutic applications.

Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.